What's Happening?
Lumicell, a company specializing in intraoperative fluorescence imaging technology, has announced its expanded participation at the American Society of Breast Surgeons (ASBrS) 2026 Annual Meeting. The
event, held at the Seattle Convention Center, features Lumicell's hands-on technology demonstrations and scientific presentations. The company is showcasing its LumiSystem, designed to detect residual cancer in breast cavities post-lumpectomy. Lumicell's presence includes educational sponsorships and clinical discussions aimed at advancing intraoperative cancer detection. The company is also highlighting its technology in a scientific poster session, contributing to the evidence supporting fluorescence-guided surgery.
Why It's Important?
Lumicell's advancements in fluorescence imaging technology represent significant progress in breast cancer surgery, potentially improving surgical outcomes by aiding in the complete removal of cancerous tissue. This technology could reduce the need for additional surgeries, thereby decreasing patient stress and healthcare costs. The company's engagement at the ASBrS meeting underscores its commitment to supporting surgeons with innovative tools that enhance decision-making during operations. As breast cancer remains a prevalent health issue, such technological advancements are crucial in improving patient care and outcomes.
